Actualités

Novanta Inc (NOVT) delivered robust Q2 2026 results with 9% organic growth, record cash flow, and raised full-year guidance following the Riverpoint Medical acquisition.

Novanta (NASDAQ:NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra sa

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) will be announcing earnings results this Monday after market close. Here’s what to expect.

This is Ray Nash, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; and our Chief Financial Officer, Robert Buckley. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued last night and also those in our SEC filings.

Novanta Inc (NOVT) reports impressive revenue and bookings growth, driven by AI and robotics, while navigating cost pressures and geopolitical uncertainties.

Novanta (NASDAQ:NOVT) reported stronger-than-expected first-quarter 2026 results, with management citing broad-based bookings growth, accelerating demand in automation and medical markets, and rising exposure to artificial intelligence-related infrastructure applications. Chair and Chief Executive

Moby summary of Novanta Inc.'s Q1 2026 earnings call

Novanta (NOVT) delivered earnings and revenue surprises of +3.85% and +1.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?